December 19, 2016 News

New York Times: “Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits”

December 19, 2016

Matt Richtel and Andrew Pollack

Enthusiasm for cancer immunotherapy is soaring, and so is Arie Belldegrun’s fortune.

Dr. Belldegrun, a physician, co-founded Kite Pharma, a company that could be the first to market next year with a highly anticipated new immunotherapy treatment. But even without a product, Dr. Belldegrun has struck gold.

His stock in Kite is worth about $170 million. Investors have profited along with him, as the company’s share price has soared to about $50 from an initial price of $17 in 2014.


Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.